MRK | Weekly | Haru Insights

The U.S. FDA’s approval of LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor, marks a transformative milestone for Merck (MRK), establishing a first-in-class therapy with 56–59% LDL cholesterol reduction and positioning MRK at the forefront of cardiovascular innovation.
The FDA’s expanded approval of Keytruda in combination with Padcev for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer—removing cisplatin eligibility as a barrier—solidifies Keytruda’s dominance in immuno-oncology and extends its commercial potential across a high-unmet-need indication.

Lipfendra’s breakthrough approval signals a paradigm shift in cardiovascular care, delivering a potent, oral alternative to injectable PCSK9 inhibitors—offering Merck a rare first-in-class advantage with strong patient adherence and payer appeal.
The Keytruda+Padcev combination approval demonstrates Merck’s ability to expand its immuno-oncology franchise into earlier-stage, cisplatin-unrestricted bladder cancer, unlocking massive patient populations and reinforcing its leadership in precision oncology.
Lipfendra’s high LDL reduction (56–59%) positions it as a game-changer in hypercholesterolemia, potentially capturing significant market share from injectables while reducing treatment burden—directly boosting Merck’s cardiovascular revenue potential.
Validated synergistic partnerships with antibody-drug conjugate developers underscore Merck’s strategic agility, turning collaborations into real-world clinical wins—improving confidence in its R&D execution and commercial reach.
The dual approval momentum across cardiology and oncology illustrates Merck’s rare ability to innovate across therapeutic areas—highlighting a diversified growth engine beyond Keytruda’s patent expiry era.

Merck & Co., Inc. (MRK)[Tv]